1. Shevtsov M., Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol. 2016, 7, 171.
2. Shevtsov M. A., Komarova E. Y., Abkin S. V., Meshalkina D. A., Bychkova N. V., Aksenov N. D., Margulis B. A., Guzhova I. V. Exogenously delivered heat shock protein 70 displaces its endogenous analogue and sensitizes cancer cells to lymphocytes-mediated cytotoxicity. Oncotarget, 2014;5(10):3101–3114.
3. Shevtsov M. A., Pozdnyakov A. V., Mikhrina A. L., Yakovleva L. Y., Nikolaev B. P., Dobrodumov A. V., Meshalkina D. A., Ischenko A. M., Pitkin E., Guzhova I. V., Margulis B. A. Eff ective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70. International Journal of Cancer. 2014;135(9):2118–28.
4. Abkin S. V., Ostroumova O. S., Komarova E. Y., Meshalkina D. A., Shevtsov M. A., Margulis B. A., Guzhova I. V. Phloretin increases the anti-tumor effi cacy of intratumorally delivered heat-shock protein 70 kDa (HSP70) in a murine model of melanoma. Cancer Immunol Immunother. 2016;65(1):83–92.
5. Shevtsov M. A., Kim A. V., Samochernych K. A., Romanova I. V., Margulis B. A., Guzhova I. V., Yakovenko I. V., Ischenko A. M., Khachatryan W. A. Pilot study of intratumoral injection of recombinant heat shock protein Hsp70 in treatment of malignant brain tumors in children. OncoTargets and Therapy, 2014;7:1071–1081.